STIM trades 73.6% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STIM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Neuronetics, Inc. (STIM) has a Wall Street consensus price target of $5.00, based on estimates from 7 covering analysts. With the stock currently trading at $2.88, this represents a potential upside of +73.6%. The company has a market capitalization of $200M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STIM trades at a trailing P/E of -4.9x. Analysts expect EPS to grow +18.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ELMDElectromed, Inc. | $228M | $27.57 | $48.50 | +75.9% | Buy | 22.7x | 5 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ABSIAbsci Corporation | $1.7B | $9.74 | $13.60 | +39.6% | Buy | — | 13 |
 LIVNLivaNova PLC | $4.2B | $77.16 | $88.50 | +14.7% | Buy | 17.7x | 15 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 GKOSGlaukos Corporation | $9.1B | $153.49 | $190.75 | +24.3% | Buy | — | 25 |
 ABTAbbott Laboratories | $180.3B | $103.53 | $121.50 | +17.4% | Buy | 18.8x | 41 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
Quick answers to the most common questions about buying STIM stock.
The consensus Wall Street price target for STIM is $5, representing 73.6% upside from the current price of $2.88. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STIM has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 73.6% upside from current levels.
STIM's current price is $2.88 with a consensus target of $5 (73.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for STIM, while the most conservative target is $5. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
STIM is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STIM stock forecast based on 7 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STIM, with a "Buy" consensus rating and $5 price target (73.6% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STIM analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.